ReShape Lifesciences Inc. (RSLS)
NASDAQ: RSLS · Real-Time Price · USD
0.3650
-0.0150 (-3.95%)
At close: Apr 25, 2025, 4:00 PM
0.3614
-0.0036 (-0.99%)
After-hours: Apr 25, 2025, 7:27 PM EDT
ReShape Lifesciences Revenue
In the year 2024, ReShape Lifesciences had annual revenue of $8.01M, down -7.74%. ReShape Lifesciences had revenue of $1.81M in the quarter ending December 31, 2024, a decrease of -8.93%.
Revenue (ttm)
$8.01M
Revenue Growth
-7.74%
P/S Ratio
0.02
Revenue / Employee
$444,778
Employees
18
Market Cap
4.12M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 8.01M | -672.00K | -7.74% |
Dec 31, 2023 | 8.68M | -2.56M | -22.79% |
Dec 31, 2022 | 11.24M | -2.36M | -17.35% |
Dec 31, 2021 | 13.60M | 2.30M | 20.36% |
Dec 31, 2020 | 11.30M | -3.79M | -25.12% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
RSLS News
- 6 days ago - ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology - GlobeNewsWire
- 16 days ago - ReShape Lifesciences Inc. (RSLS) Earnings Highlights and Strategic Business Update Conference (Transcript) - Seeking Alpha
- 17 days ago - ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market - GlobeNewsWire
- 19 days ago - ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 weeks ago - RESHAPE LIFESCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ReShape Lifesciences Inc. - RSLS - Business Wire
- 6 weeks ago - ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology - GlobeNewsWire
- 2 months ago - ReShape Lifesciences® Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band® 2.0 FLEX - GlobeNewsWire
- 2 months ago - ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering - GlobeNewsWire